Latest Headlines

  1. Tasrif Pharmaceutical Granted Second U.S. Patent For CD155-Targeting Antibody Developed With Abzena's Humanization & Immunogenicity Platforms 7/31/2026

    On July 29, 2026, Abzen’s customer Tasrif Pharmaceutical, LLC announced the grant of its second U.S. Patent, expanding its intellectual property targeting the Poliovirus Receptor (CD155/PVR). 

  2. Abzena's Customer Promatix Awarded An Innovate UK Biomedical Catalyst Grant To Advance Cis-Bispecific ADC 7/31/2026

    On July 28, 2026, Promatix Biosciences Ltd, an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, announced that it has been awarded a grant under the Innovate UK Biomedical Catalyst 2025: Industry-led R&D small projects competition. 

  3. Virtual Pharma Expo Launches Searchable Six-Year Equipment Demo Archive Ahead Of September Solid Dosage Event 7/30/2026

    Virtual Pharma Expo has launched a redesigned website that gives pharmaceutical manufacturing teams one place to watch every past equipment demonstration and register for upcoming live events.

  4. AGC Biologics Lands Commercial Manufacturing Agreement For Yokohama Site Worth Hundreds Of Millions Of Dollars 7/28/2026

    Ahead of the official opening of AGC Biologics’ Yokohama site, an international biopharmaceutical company has already secured half of the facility’s mammalian manufacturing capacity with a multi-year commercial contract expected to reach hundreds of millions of dollars in total value. 

  5. New Carrying Straps Simplify Handling Of Meissner's 16 L CryoVault® Container 7/27/2026
  6. Kyverna Therapeutics And ElevateBio Enter Into Commercial Manufacturing And Supply Agreement For Miv-cel 7/27/2026

    Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19 directed CAR T-cell therapy.

  7. FUJIFILM Biosciences And NextCell Launch New Commercial Platform Comprised Of RUO Stromal Cells And Cell Culture Media 7/27/2026
  8. Rezon Bio Appoints Dr. Hubert Scholze As Chief Business Officer To Accelerate Global Commercial Expansion 7/20/2026
  9. Kindeva Appoints Brok Weichbrodt As Chief Transformation Officer To Accelerate Growth Strategy And Commercial Excellence 7/14/2026
  10. Cytovance Biologics Launches In-House Cell Line Development With High-Yield Titers Up To 10g/L 7/13/2026